Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Catalyst Pharmaceuticals (CPRX) over the last 8 years, with Q3 2025 value amounting to $40.5 million.

  • Catalyst Pharmaceuticals' Change in Receivables rose 360621.57% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year increase of 37120.49%. This contributed to the annual value of $12.0 million for FY2024, which is 7222.98% down from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Change in Receivables stood at $40.5 million, which was up 360621.57% from -$5.4 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Receivables registered a high of $40.5 million during Q3 2025, and its lowest value of -$5.4 million during Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Change in Receivables value was $1.1 million (recorded in 2022), while the average stood at $5.3 million.
  • Examining YoY changes over the last 5 years, Catalyst Pharmaceuticals' Change in Receivables showed a top increase of 1846666.67% in 2022 and a maximum decrease of 23965.27% in 2022.
  • Over the past 5 years, Catalyst Pharmaceuticals' Change in Receivables (Quarter) stood at -$6000.0 in 2021, then skyrocketed by 18466.67% to $1.1 million in 2022, then soared by 395.92% to $5.5 million in 2023, then soared by 31.93% to $7.2 million in 2024, then skyrocketed by 462.36% to $40.5 million in 2025.
  • Its Change in Receivables was $40.5 million in Q3 2025, compared to -$5.4 million in Q2 2025 and $5.8 million in Q1 2025.